The Post-Humira Era
How adalimumab biosimilar competition is reshaping biologic access and affordability
Key Points
- Humira (adalimumab) lost US market exclusivity in January 2023 — the first adalimumab biosimilars launched that month
- Eight adalimumab biosimilars are now FDA-approved, with several holding interchangeable designation
- Despite biosimilar entry, Humira remains widely used thanks to AbbVie's strong copay program
- Biosimilar competition has created new options for uninsured patients and expanded formulary choices
- The post-Humira era signals how future biologic patent expirations (Stelara, Dupixent) will reshape the market
Why Humira's Patent Expiration Matters
Humira was the world's best-selling drug for over a decade, generating over $20 billion in annual global sales at its peak. Its US patent expiration was one of the most anticipated events in pharmaceutical history — the first true test of whether the US biosimilar market could function the way generic drug markets do for small molecules.
The results have been more nuanced than initially expected. While eight biosimilars have launched, market penetration has been slower than many predicted — largely because AbbVie's robust rebate system with pharmacy benefit managers (PBMs) and its strong patient copay program have maintained Humira's commercial position.
What Changed for Patients
✅ More Options
Patients now have eight FDA-approved adalimumab options. For those whose insurance places Humira on a high tier, biosimilars may offer lower cost-sharing.
✅ Uninsured Savings
Cash-paying uninsured patients may pay significantly less for certain adalimumab biosimilars versus Humira's list price. Yusimry launched with a dramatically lower list price.
⚠️ Complexity
More options means more complexity in insurance coverage, formulary placement, and PA requirements. BiologicHealthPlus navigates this for every patient.
📊 Insured Patients
Most commercially insured patients still pay $0–$35/month for Humira via myAbbVie Assist — making the biosimilar cost comparison less clear-cut than it first appears.
What Comes Next: Upcoming Biologic Patent Expirations
| Medication | Manufacturer | US Patent Expiration (approx) | Annual US Sales (approx) |
|---|---|---|---|
| Stelara | Janssen | 2023–2025 (biosimilars launching) | ~$10B |
| Enbrel | Amgen/Pfizer | Complex patent situation; limited biosimilar competition expected | ~$4B |
| Dupixent | Sanofi/Regeneron | Early 2030s | ~$14B |
| Skyrizi | AbbVie | Late 2030s | ~$8B (growing) |
💊 BiologicHealthPlus Navigates the Post-Humira Landscape For You
We compare Humira and all adalimumab biosimilars on your insurance plan to find the lowest cost option — then handle all prior authorization and enrollment.
Humira Biosimilar Guide →📚 Sources & Further Reading
Content developed with reference to leading health organizations, peer-reviewed research, and FDA prescribing information.
Medical Disclaimer: Educational content reviewed by the BiologicHealthPlus Clinical Team. Consult your healthcare provider for personalized advice. Last reviewed: August 2026.